Shopping Cart
  • Remove All
  • TargetMol
    Your shopping cart is currently empty
Filter
Applied FilterClear all
TargetMol | Tags By Target
  • mTOR
    (71)
  • PI3K
    (40)
  • Autophagy
    (27)
  • Apoptosis
    (23)
  • DNA-PK
    (11)
  • Akt
    (8)
  • ATM/ATR
    (3)
  • Endogenous Metabolite
    (3)
  • Src
    (3)
  • Others
    (17)
Filter
Search Result
Results for "

mammalian target of rapamycin

" in TargetMol Product Catalog
  • Inhibitors & Agonists
    93
    TargetMol | Inhibitors_Agonists
  • Compound Libraries
    1
    TargetMol | Compound_Libraries
  • PROTAC Products
    1
    TargetMol | PROTAC
  • Natural Products
    13
    TargetMol | Natural_Products
  • Recombinant Protein
    2
    TargetMol | Recombinant_Protein
  • Antibody Products
    2
    TargetMol | Antibody_Products
AZD-8055
T18591009298-09-2
AZD8055 is an ATP-competitive mTOR inhibitor (IC50: 0.8 nM in MDA-MB-468 cells). It is ~1,000-fold selective for mTOR over all PI3K isoforms.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Rapamycin
Sirolimus, NSC-2260804, AY 22989
T153753123-88-9
Rapamycin (AY 22989) is a natural product of macrolides, an mTOR inhibitor with specificity (HEK293 cells: IC50=0.1 nM). Rapamycin has immunosuppressive activity and induces autophagy.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
Torin 1
T60451222998-36-8
Torin 1 is an effective inhibitor of mTORC1 2 with (IC50: 2 nM 10 nM); has 1000-fold selectivity for mTOR than PI3K.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
MHY1485
T1908326914-06-1
MHY1485 is an mTOR activator that is cell-permeable. MHY1485 inhibits autophagosome and lysosome fusion, leading to accumulation of LC3II proteins and increased autophagosomes, thereby inhibiting cellular autophagy.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Hot
TargetMol | Citations Cited
wye-132
WYE-125132, WYE125132, WYE 125132
T63461144068-46-1In house
WYE-125132 (WYE-132 (WYE-125132)) is a highly potent, ATP-competitive mTOR inhibitor with IC50 of 0.19 nM; highly selective for mTOR versus PI3Ks or PI3K-related kinases hSMG1 and ATR.
  • Inquiry Price
8-10weeks
Size
QTY
TargetMol | Citations Cited
way-600
WAY600
T67301062159-35-6In house
WAY-600 is a potent, ATP-competitive, and selective inhibitor of mTOR with an IC50 of 9 nM; it blocks mTORC1 P-S6K(T389) and mTORC2 P-AKT(S473) but not P-AKT(T308), and is selective for mTOR over PI3Kα (>100-fold) and PI3Kγ (>500-fold).
  • Inquiry Price
8-10weeks
Size
QTY
TargetMol | Inhibitor Sale
mTOR inhibitor-3
T121231207358-59-5In house
mTOR inhibitor-3 is a selective mTOR inhibitor (Ki= 1.5 nM). mTOR inhibitor-3 inhibits mTORC1 and mTORC2 in cellular and in vivo experiments.
  • Inquiry Price
6-8 weeks
Size
QTY
GDC-0349
RG-7603
T65101207360-89-1In house
GDC-0349 (RG-7603) is a potent and selective ATP-competitive inhibitor of mTOR with Ki of 3.8 nM, 790-fold inhibitory effect against PI3Kα and other 266 kinases. Phase 1.
  • Inquiry Price
8-10weeks
Size
QTY
TargetMol | Citations Cited
(+)-Usnic acid
D-Usnic Acid, (+)-Usniacin
T63547562-61-0
(+)-Usnic acid (D-Usnic Acid) is a naturally occurring dibenzofuran derivative found in several lichen species.
  • Inquiry Price
Size
QTY
L-Leucine
Leu, (S)-Leucine
T3O274961-90-5
L-Leucine ((S)-Leucine) is one of nine essential amino acids in humans (provided by food), L-Leucine is important for protein synthesis and many metabolic functions. L-Leucine contributes to regulation of blood-sugar levels; growth and repair of muscle and bone tissue; growth hormone production; and wound healing. L-Leucine also prevents breakdown of muscle proteins after trauma or severe stress and may be beneficial for individuals with phenylketonuria. L-Leucine is available in many foods and deficiency is rare.
  • Inquiry Price
Size
QTY
PP121
T24151092788-83-4
PP-121 is a multi-targeted inhibitor of PDGFR (IC50: 2 nM), Hck (IC50: 8 nM), mTOR (IC50: 10 nM), VEGFR2(IC50: 12 nM), Src (IC50: 14 nM) and Abl (IC50: 18 nM) , also inhibits DNA-PK (IC50: 60 nM).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
osi-027
OSI027, ASP4786
T6319936890-98-1
OSI-027 (ASP4786) is a selective and potent dual inhibitor of mTORC1 and mTORC2 with IC50 of 22 nM and 65 nM, and more than 100-fold selectivity observed for mTOR than PI3Kα, PI3Kβ, PI3Kγ or DNA-PK. Phase 1.
  • Inquiry Price
Size
QTY
TargetMol | Citations Cited
pf-04691502
PF4691502
T62511013101-36-4
PF-04691502 is a potent and selective inhibitor of PI3K and mTOR kinases with antitumor activity.
  • Inquiry Price
Size
QTY
TargetMol | Citations Cited
Dactolisib
NVP-BEZ235, BEZ235
T2235915019-65-7
Dactolisib (BEZ235) is an orally bioavailable inhibitor of PI3K and mTOR, with IC50 values of 4 nM for p110α, 5 nM for p110γ, 7 nM for p110δ, 75 nM for p110β, and 20.7 nM for mTOR.
  • Inquiry Price
Size
QTY
TargetMol | Citations Cited
Everolimus
SDZ-RAD, RAD001
T1784159351-69-6
Everolimus (SDZ-RAD) is a potent mTOR inhibitor that binds to FKBP-12. It is used alone or in combination with calcineurin inhibitors.
  • Inquiry Price
Size
QTY
TargetMol | Citations Cited
Vistusertib
AZD2014
T19611009298-59-2
Vistusertib (AZD2014) is an orally bioavailable inhibitor of the mammalian target of rapamycin (mTOR) with potential antineoplastic activity.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
ETP-46464
T20841345675-02-6
ETP-46464 is an effective and specific ATR inhibitor (IC50: 25 nM).
  • Inquiry Price
Size
QTY
TargetMol | Citations Cited
XL388
T60301251156-08-7
XL388 is a highly effective, specifc, ATP-competitive inhibitor of mTOR ( IC50: 9.9 nM), 1000-fold selectivity than the closely related PI3K kinases.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
torin 2
T61001223001-51-1
Torin 2(IC50=0.25 nM), a specific and effective mTOR inhibitor, is the 800-fold greater specific activity for mTOR than PI3K and improves pharmacokinetic properties. The EC50 of Torin 2 for ATM ATR DNA-PK inhibition is 28 nM 35 nM 118 nM, respectively.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
TargetMol | Citations Cited
KU-0060648
KU0060648
T6557881375-00-4
KU-0060648 is a dual inhibitor of DNA-PK and PI3Kα, PI3Kβ, PI3Kδ with IC50 values of 8.6 nM, 4 nM, 0.5 nM, and 0.1 nM respectively, and demonstrates less inhibition of PI3Kγ with an IC50 of 0.59 μM.
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
MTI-31
MTI-31, LXI-15029
T353431567915-38-1
MTI-31 (LXI-15029) is a potent, orally active, and highly selective inhibitor of mTORC1 and mTORC2, exhibiting a Kd of 0.20 nM for mTOR and >5,000-fold selectivity over PIK3CA, PIK3CB, and PIK3G in binding assays, with an IC50 of 39 nM for mTOR in a LANCE assay of mTOR substrate phosphorylation with 100 μM ATP [1].
  • Inquiry Price
6-8 weeks
Size
QTY
TargetMol | Inhibitor Sale
wye-687
T67321062161-90-3
WYE-687 is an ATP-competitive and selective inhibitor of mTOR with an IC50 of 7 nM; it blocks mTORC1 pS6K(T389) and mTORC2 P-AKT(S473) without affecting P-AKT(T308). Its selectivity for mTOR is greater than PI3Kα (>100-fold) and PI3Kγ (>500-fold).
  • Inquiry Price
Size
QTY
TargetMol | Inhibitor Sale
VS-5584
VS5584, VS 5584, SB2343
T61031246560-33-7
VS-5584 (SB2343) is a pan-PI3K mTOR kinase inhibitor.
  • Inquiry Price
Size
QTY
Bimiralisib
PQR309, PI3K-IN-2, 5-(4,6-dimorpholino-1,3,5-triazin-2-yl)-4-(trifluoromethyl)pyridin-2-amine
T22651225037-39-7
Bimiralisib (PI3K-IN-2) is an orally bioavailable pan inhibitor of PI3K and inhibitor of the mTOR, with potential antineoplastic activity. PI3K-IN-2 inhibits the PI3K kinase isoforms alpha, beta, gamma and delta and, to a lesser extent, mTOR kinase, which may result in tumor cell apoptosis and growth inhibition in cells overexpressing PI3K mTOR. Activation of the PI3K mTOR pathway promotes cell growth, survival, and resistance to both chemotherapy and radiotherapy.
  • Inquiry Price
Size
QTY